Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Viktoria Bergqvist

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
A new Simple Endoscopic Score for Ulcerative Colitis - the SES-UCViktoria Bergqvist, Peter Gedeon, Erik Hertervig, et al.
Alimentary Pharmacology & Therapeutics|April 26, 2022
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel diseaseViktoria Bergqvist, Johanna Holmgren, Daniel Klintman, et al.
Acta Oncologica (Stockholm, Sweden)|October 7, 2025
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature reviewHenrik Ekedahl, Gudbjörg Sigurjonsdottir, Viktoria Bergqvist, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2017
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitisViktoria Bergqvist, Erik Hertervig, Peter Gedeon, et al.
Therapeutic Advances in Gastroenterology|October 23, 2018
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel diseaseViktoria Bergqvist, Mohammad Kadivar, Daniel Molin, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
A new Simple Endoscopic Score for Ulcerative Colitis - the SES-UCViktoria Bergqvist, Peter Gedeon, Erik Hertervig, et al.
Alimentary Pharmacology & Therapeutics|April 26, 2022
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel diseaseViktoria Bergqvist, Johanna Holmgren, Daniel Klintman, et al.
Acta Oncologica (Stockholm, Sweden)|October 7, 2025
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature reviewHenrik Ekedahl, Gudbjörg Sigurjonsdottir, Viktoria Bergqvist, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2017
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitisViktoria Bergqvist, Erik Hertervig, Peter Gedeon, et al.
Therapeutic Advances in Gastroenterology|October 23, 2018
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel diseaseViktoria Bergqvist, Mohammad Kadivar, Daniel Molin, et al.
Pageof 1